Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (861-870 of 968) with videos related to

Pageof 97
Sort By:
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
American Journal of Hematology|October 26, 2017
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myelomaArjun Lakshman, Preet Paul Singh, S Vincent Rajkumar, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
Bone Marrow Transplantation|December 23, 2017
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Morie A Gertz, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Pageof 97

Showing results (861-870 of 968) with videos related to

Sort By:
Pageof 97
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
American Journal of Hematology|October 26, 2017
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myelomaArjun Lakshman, Preet Paul Singh, S Vincent Rajkumar, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
Bone Marrow Transplantation|December 23, 2017
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Morie A Gertz, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Pageof 97